Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

INTRODUCTION: This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). METHODS: Eligible patients who had received ≤1 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Dent, Rebecca A, Lindeman, Geoffrey J, Clemons, Mark, Wildiers, Hans, Chan, Arlene, McCarthy, Nicole J, Singer, Christian F, Lowe, Elizabeth S, Watkins, Claire L, Carmichael, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979135/
https://www.ncbi.nlm.nih.gov/pubmed/24063698
http://dx.doi.org/10.1186/bcr3484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979135/
https://www.ncbi.nlm.nih.gov/pubmed/24063698
http://dx.doi.org/10.1186/bcr3484

Ejemplares similares